Valneva: Phase 1 trial initiated in the Zika virus
There are no preventive vaccines or effective treatments against the Zika virus, which therefore remains a public health threat and has been included in the FDA's priority review voucher program for tropical diseases", he points out.
The trial is expected to include around 150 participants aged 18 to 49 in the USA. Participants will receive a low, medium or high dose of VLA1601. Initial data from the trial are expected in the first half of 2025.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction